Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
FDA Issues Complete Response Letter for Biohavens VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
FDA Issues Complete Response Letter for Biohavens VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical